$BHC earnings report

Bausch Health Announces Third Quarter 2026 Results, Raises Guidance. AlphAI read Bausch Health Companies's third quarter 2026 filing as strong. 2 quarters are on record below.

third quarter 2026

AlphAI · Earnings readBHC · third quarter 2026 · ended September 30, 2026

Bausch Health Announces Third Quarter 2026 Results, Raises Guidance

✓Strong quarter

Consolidated revenue increased 10%, GAAP net income attributable to Bausch Health increased to $436 million from $179 million, adjusted EBITDA attributable to Bausch Health increased to $1,305 million from $986 million, and the Company raised full-year revenue, adjusted EBITDA and adjusted cash flows from operations guidance for Bausch Health excluding Bausch + Lomb.

Revenue
$2.94B
10% y/y
Salix segment
$831M
16% reported; 14% organic y/y
EPS · GAAP
$1.15
full year 2026, current guidance as of October 28, 2026 outlook
BHC: $10.975 - $11.175 billion; BHC (excl. B+L): $5.525 - $5.625 billion; B+L: $5.450 - $5.550 billion

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total consolidated revenues, three months ended September 30, 2026GAAP$2.94B–10%
Total consolidated revenues, nine months ended September 30, 2026GAAP$8.32B–11%
Product sales, three months ended September 30, 2026GAAP$2.91B––
Other revenues, three months ended September 30, 2026GAAP$29M––
Operating income, three months ended September 30, 2026GAAP$983M––
Operating income, nine months ended September 30, 2026GAAP$773M––
Net income, three months ended September 30, 2026GAAP$446M––
Net income attributable to Bausch Health Companies Inc., three months ended September 30, 2026GAAP$436M––
Net income attributable to Bausch Health Companies Inc., nine months ended September 30, 2026GAAP−$729M––
Adjusted net income attributable to Bausch Health Companies Inc., three months ended September 30, 2026non-GAAP$673M––
Adjusted net income attributable to Bausch Health Companies Inc., nine months ended September 30, 2026non-GAAP$1.45B––
Diluted earnings per share attributable to Bausch Health Companies Inc., three months ended September 30, 2026GAAP$1.15––
Adjusted earnings per share attributable to Bausch Health Companies Inc., three months ended September 30, 2026non-GAAP$1.77–53%
Diluted earnings per share attributable to Bausch Health Companies Inc., nine months ended September 30, 2026GAAP$ (1.95)––
Adjusted earnings per share attributable to Bausch Health Companies Inc., nine months ended September 30, 2026non-GAAP$ 3.81––
Adjusted EBITDA attributable to Bausch Health Companies Inc., three months ended September 30, 2026non-GAAP$1.30B––
Adjusted EBITDA attributable to Bausch Health Companies Inc., nine months ended September 30, 2026non-GAAP$3.22B––
Cash provided by operating activities, three months ended September 30, 2026GAAP$813M–101%
Cash provided by operating activities, nine months ended September 30, 2026GAAP$1.71B––
Adjusted cash flows from operations, three months ended September 30, 2026non-GAAP$782M––
Adjusted cash flows from operations, nine months ended September 30, 2026non-GAAP$1.79B––
Cost of goods sold excluding amortization and impairments of intangible assets, three months ended September 30, 2026GAAP$721M––
Selling, general and administrative, three months ended September 30, 2026GAAP$834M––
Research and development, three months ended September 30, 2026GAAP$141M––
Provision for income taxes, three months ended September 30, 2026GAAP$151M––

Segments

SegmentRevenueq/qy/y
Salix segmentXifaxan® was the primary contributor to growth, with 16% revenue growth in the third quarter of 2026.$831M–16% reported; 14% organic
International segmentLed by Canada.$299M–5% reported; 4% organic
Solta Medical segmentReported growth was aided by the acquisition of the full service distributor in China; the Asia Pacific region decreased modestly on an organic basis.$165M–18% reported; (4%) organic
Diversified segmentOrganic revenue growth was primarily driven by double-digit growth in Dermatology.$271M–5% reported; 5% organic
Bausch + Lomb segmentNo specific segment driver was stated.$1.38B–7% reported; 7% organic
Bausch + Lomb Vision CareNo specific subsegment driver was stated.$774M–5% reported; 5% organic
Bausch + Lomb SurgicalNo specific subsegment driver was stated.$234M–9% reported; 8% organic
Bausch + Lomb PharmaceuticalsNo specific subsegment driver was stated.$367M–11% reported; 11% organic

Amounts quoted below without a unit are in millions, as in the filing’s tables. Per-share figures are as printed.

full year 2026, current guidance as of October 28, 2026 outlook

  • RevenueBHC: $10.975 - $11.175 billion; BHC (excl. B+L): $5.525 - $5.625 billion; B+L: $5.450 - $5.550 billion
  • NoteBHC revenue growth vs. prior year: 7% - 9%
  • NoteBHC adjusted EBITDA: $4.315 - $4.415 billion
  • NoteBHC (excl. B+L) adjusted EBITDA: $3.225 - $3.275 billion
  • NoteB+L adjusted EBITDA: $1.090 - $1.140 billion
  • NoteBHC adjusted EBITDA growth vs. prior year: 12% - 14%
  • NoteBHC (excl. B+L) adjusted cash flows from operations: $1.600 - $1.675 billion

Capital returns

  • Board of Directors authorized a $50 million share repurchase program, with the primary objective of offsetting dilution associated with the anticipated vesting of management equity awards in 2027.

What drove it

  • Total consolidated reported revenue increased $260 million, or 10%, to $2.94 billion; acquisitions contributed $37 million and divestitures and discontinuations contributed $11 million to the organic-revenue reconciliation.
  • Bausch Health excluding Bausch + Lomb generated 12% reported revenue growth and 8% organic revenue growth.
  • Salix grew 16% on a reported basis and 14% on an organic basis, led by Xifaxan®.
  • Bausch + Lomb revenue increased 7% on both a reported and organic basis.
  • Consolidated adjusted EBITDA attributable to Bausch Health increased $319 million to $1,305 million.
  • The Company stated that quarterly adjusted EBITDA excluding Bausch + Lomb exceeded $1 billion for the first time, at $1,022 million.

Concerns

  • Solta Medical organic revenue decreased (4%), after reported growth was aided by the acquisition of the full service distributor in China; the Asia Pacific region decreased modestly.
  • Nine-month operating income was $ 773 (in millions), compared with $ 1,339 (in millions), and nine-month net loss attributable to Bausch Health Companies Inc. was $ (729) (in millions), compared with net income of $ 269 (in millions).
  • The Company recorded $ 1,426 (in millions) of goodwill impairments during the nine months ended September 30, 2026.
  • Total long-term debt and other was $20,637 million as of September 30, 2026.
  • The Company cited uncertainty surrounding tariffs, retaliatory tariffs and other trade protectionist measures, stating that there can be no assurance their impacts will not be adverse.

What to watch

  • Delivery against full-year BHC revenue guidance of $10.975 - $11.175 billion and adjusted EBITDA guidance of $4.315 - $4.415 billion.
  • Delivery against Bausch Health excluding Bausch + Lomb adjusted cash flows from operations guidance of $1.600 - $1.675 billion.
  • Whether Salix and Xifaxan® continue to support organic revenue growth.
  • Solta Medical organic revenue performance and the Asia Pacific region.
  • Cash generation, debt reduction and management of the debt maturity profile.
  • Progress in evaluating options to unlock shareholder value, including maximizing the value of Bausch Health and Bausch + Lomb assets.

Balance sheet and cash flow

  • Cash and cash equivalents were $2,485 million as of September 30, 2026, compared with $1,309 million as of December 31, 2025.
  • Total long-term debt and other, net of premiums, discounts and issuance costs was $20,168 million as of September 30, 2026, compared with $20,232 million as of December 31, 2025.
  • Total long-term debt and other was $20,637 million as of September 30, 2026, compared with $20,817 million as of December 31, 2025.
  • Cash provided by operating activities was $813 million for the three months ended September 30, 2026, compared with $405 million for the three months ended September 30, 2025.
  • Bausch Health excluding Bausch + Lomb generated $581 million in cash provided by operating activities and $539 million in adjusted cash flows from operations for the three months ended September 30, 2026.

Analysis

Bausch Health reported a strong third quarter. Consolidated revenue was $2.94 billion, up 10% from $2.68 billion, with 8% organic growth. Growth was broad across the reported segments, including 16% reported growth at Salix, 5% at International, 5% at Diversified and 7% at Bausch + Lomb. Salix was led by Xifaxan®, while Diversified benefited from double-digit Dermatology growth.

Profitability improved materially in the quarter. GAAP operating income increased to $983 million from $619 million, GAAP net income attributable to Bausch Health increased to $436 million from $179 million, and diluted GAAP EPS increased to $1.15 from $0.48. Adjusted net income attributable to Bausch Health was $673 million versus $434 million, adjusted EPS was $1.77 versus $1.16, and adjusted EBITDA attributable to Bausch Health increased to $1,305 million from $986 million. Bausch Health excluding Bausch + Lomb produced $1,022 million of adjusted EBITDA, its first quarter above $1 billion.

Mix and underlying growth require attention. Solta Medical reported 18% revenue growth, but organic revenue declined (4%) because the reported result was aided by the acquisition of the full service distributor in China and the Asia Pacific region decreased modestly. In contrast, Bausch + Lomb posted 7% reported and organic growth, with Pharmaceuticals growing 11% reported and organic, Surgical growing 9% reported and 8% organic, and Vision Care growing 5% reported and organic.

Cash generation was substantial. Consolidated cash provided by operating activities rose to $813 million from $405 million, while adjusted cash flows from operations were $782 million compared with $508 million. Cash and cash equivalents rose to $2,485 million from $1,309 million at December 31, 2025. Total long-term debt and other was $20,637 million at September 30, 2026, compared with $20,817 million at year end. The Board also authorized a $50 million share repurchase program intended primarily to offset anticipated management-equity-award dilution in 2027.

Management raised full-year 2026 guidance. Consolidated revenue guidance is $10.975 - $11.175 billion, with adjusted EBITDA guidance of $4.315 - $4.415 billion. Bausch Health excluding Bausch + Lomb guided revenue of $5.525 - $5.625 billion, adjusted EBITDA of $3.225 - $3.275 billion and adjusted cash flows from operations of $1.600 - $1.675 billion. The release also identifies tariff-related uncertainty, and the nine-month results include a $ 1,426 (in millions) goodwill impairment, leaving year-to-date GAAP operating income and net income below the prior-year period despite third-quarter momentum.

Management, verbatim

Bausch Health, excluding Bausch + Lomb, delivered another solid quarter, marking fourteen consecutive quarters of year-over-year Revenue and Adjusted EBITDA growth. We also achieved an important milestone, with quarterly Adjusted EBITDA, excluding Bausch + Lomb, exceeding $1 billion for the first time. Our performance reflects disciplined execution across the portfolio, with healthy cash generation supporting more than $500 million of net debt reduction during the quarter. These results give us confidence to again raise our full year 2026 guidance. We remain focused on operational excellence, sustainable growth, and long-term value creation.

Thomas J. Appio, Chief Executive Officer, Bausch Health

Not in the filing

stated, not guessed
  • Gross margin was not reported.
  • Free cash flow was not reported.
  • GAAP tax rate was not reported.
  • Quarter-over-quarter comparisons were not reported.
  • Prior-quarter financial metrics were not reported.
  • Dividend information was not reported.
  • Previous-release outlook was not provided, so comparison of actual results with prior guidance is unavailable.
  • A reconciliation of forward-looking adjusted EBITDA and adjusted cash flows from operations to GAAP measures was not provided.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

second quarter 2026

AlphAI · Earnings readBHC · second quarter 2026 · ended June 30, 2026

Bausch Health announced second quarter 2026 consolidated revenues of $2.85 billion, up 13% on a Reported basis, and raised full-year 2026 guidance.

✓Strong quarter

Revenue growth was broad-based, consolidated operating income and net income increased substantially, adjusted EBITDA grew 28%, operating cash flow increased 132%, and the Company raised full-year revenue, adjusted EBITDA, and adjusted cash flows from operations guidance for Bausch Health excluding Bausch + Lomb.

Revenue
$2.85B
13% y/y
Salix segment
$758M
21% y/y
EPS · GAAP
$0.68
full-year 2026 outlook
BHC: $10.790 - $11.040 billion

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total Bausch Health RevenuesGAAP$2.85B–13%
Total Bausch Health revenue change at constant currencynon-GAAP12%––
Total Bausch Health organic revenue changenon-GAAP11%––
Bausch Health excluding Bausch + Lomb revenuesGAAP$1.46B–16%
Bausch Health excluding Bausch + Lomb revenue change at constant currencynon-GAAP15%––
Bausch Health excluding Bausch + Lomb organic revenue changenon-GAAP13%––
Consolidated operating incomeGAAP$740M––
Consolidated net income attributable to Bausch HealthGAAP$258M––
GAAP net incomeGAAP$260M––
Consolidated adjusted net income attributable to Bausch Healthnon-GAAP$476M––
Consolidated earnings per share attributable to Bausch Health, dilutedGAAP$0.68––
Consolidated adjusted earnings per share attributable to Bausch Healthnon-GAAP$1.26–40%
Consolidated adjusted EBITDA attributable to Bausch Healthnon-GAAP$1.07B–28%
Cash provided by operating activitiesGAAP$671M–132%
Adjusted Cash Flows from Operations, Bausch Health excluding Bausch + Lombnon-GAAP$471M––
Cash and cash equivalentsGAAP$1.82B––

Segments

SegmentRevenueq/qy/y
Salix segmentSegment revenues increased 21% on an organic basis compared with the second quarter of 2025. Xifaxan® was the primary contributor to growth, with 26% revenue growth in the second quarter of 2026.$758M–21%
International segmentExcluding the impact of foreign exchange of $12 million, segment revenues grew 5% on an organic basis compared with the second quarter of 2025, with strong execution across LATAM and EMEA more than offsetting softer results in Canada.$305M–10%
Solta Medical segmentGrowth was aided by the acquisition of the full service distributor in China. Excluding a $1 million favorable impact from foreign exchange and acquisitions of $32 million, segment revenues increased by 12% on an organic basis, led by growth in APAC including South Korea, China and Taiwan.$176M–38%
Diversified segmentSegment revenues were flat on an organic basis compared with the second quarter of 2025. Results in the Neuroscience business balanced softer performance in Dermatology, Generics, and Dentistry.$219M–— %
Bausch + Lomb segmentExcluding the impact of foreign exchange of $12 million, acquisitions of $3 million and divestitures and discontinuations of $5 million, segment revenues increased 8% on an organic basis compared with the second quarter of 2025.$1.39B–9%

full-year 2026 outlook

  • RevenueBHC: $10.790 - $11.040 billion
  • NoteBHC excluding Bausch + Lomb Revenues: $5.350 - $5.500 billion
  • NoteBausch + Lomb Revenues: $5.440 - $5.540 billion
  • NoteRevenue growth vs. Prior Year: 4% - 6%
  • NoteBHC Adjusted EBITDA (non-GAAP): $4.050 - $4.175 billion
  • NoteBHC excluding Bausch + Lomb Adjusted EBITDA (non-GAAP): $3.025 - $3.100 billion
  • NoteBausch + Lomb Adjusted EBITDA (non-GAAP): $1.025 - $1.075 billion
  • NoteAdjusted EBITDA growth vs. Prior Year: 8% - 11%
  • NoteBHC excluding Bausch + Lomb Adjusted Cash Flows from Operations (non-GAAP): $1.400 - $1.475 billion

What drove it

  • Total consolidated reported revenues increased $322 million, or 13%, with organic revenue growth of 11%.
  • Bausch Health excluding Bausch + Lomb delivered its thirteenth consecutive quarter of year-over-year revenue growth, with reported revenue growth of 16% and organic revenue growth of 13%.
  • Salix growth was primarily driven by Xifaxan® revenue growth of 26%.
  • Solta Medical growth included the acquisition of the full service distributor in China and APAC growth including South Korea, China and Taiwan.
  • Consolidated operating income increased primarily due to results in the Salix, Bausch + Lomb, and Solta Medical segments.
  • Adjusted net income increased primarily due to higher revenues.

Concerns

  • International segment organic revenue growth was 5%, as strong execution across LATAM and EMEA more than offset softer results in Canada.
  • Diversified segment revenue was flat, with Neuroscience balancing softer performance in Dermatology, Generics, and Dentistry.
  • The Company cited uncertainty from the evolving landscape of tariffs, retaliatory tariffs and other trade protectionist measures, and stated that impacts could be adverse.
  • The Company does not provide a reconciliation of forward-looking Adjusted EBITDA or Adjusted Cash Flows from Operations to GAAP measures because adjustments may be material and cannot be forecast with reasonable certainty.

What to watch

  • Delivery against full-year 2026 BHC revenue guidance of $10.790 - $11.040 billion and adjusted EBITDA guidance of $4.050 - $4.175 billion.
  • Delivery against Bausch Health excluding Bausch + Lomb revenue guidance of $5.350 - $5.500 billion, adjusted EBITDA guidance of $3.025 - $3.100 billion, and adjusted cash flows from operations guidance of $1.400 - $1.475 billion.
  • The trajectory of Salix and Xifaxan® growth, International performance in Canada, and the organic contribution from Solta Medical after the China distributor acquisition.
  • The direct and indirect effects of tariffs and related trade measures.
  • The Company's evaluation of options for unlocking shareholder value, including maximizing the value of its Bausch Health and Bausch + Lomb assets.

Balance sheet and cash flow

  • Cash provided by operating activities was $671 million in the second quarter of 2026, compared with $289 million in the second quarter of 2025.
  • Bausch Health excluding Bausch + Lomb generated $471 million in Adjusted Cash Flows from Operations (non-GAAP).
  • Consolidated cash and cash equivalents were $1,825 million as of June 30, 2026, compared with $1,309 million as of December 31, 2025.
  • The Company stated that it materially improved its debt maturity profile following major refinancing initiatives in the prior twelve-month period.

Analysis

Bausch Health reported a strong second quarter, with consolidated revenue of $2.85 billion versus $2.53 billion in the prior-year period. Reported growth was 13%, while organic revenue growth was 11%. Bausch Health excluding Bausch + Lomb grew revenue 16% on a reported basis and 13% on an organic basis, extending what the Company described as its thirteenth consecutive quarter of year-over-year revenue growth.

Growth was broad-based across the portfolio. Salix revenue increased 21%, with Xifaxan® the primary contributor and delivering 26% revenue growth. Solta Medical revenue increased 38%, aided by the China distributor acquisition, while organic revenue increased 12% and APAC contributed growth. Bausch + Lomb revenue increased 9%, with 8% organic growth. International revenue increased 10% but only 5% organically, as LATAM and EMEA execution offset softer Canada results. Diversified revenue was flat.

Profitability and cash generation improved materially. Consolidated operating income rose to $740 million from $444 million, while GAAP net income attributable to Bausch Health increased to $258 million from $148 million. Adjusted EBITDA attributable to Bausch Health increased to $1,075 million from $842 million. Cash provided by operating activities was $671 million, compared with $289 million, and Bausch Health excluding Bausch + Lomb generated $471 million in adjusted cash flows from operations.

The balance sheet showed cash and cash equivalents of $1,825 million as of June 30, 2026, compared with $1,309 million as of December 31, 2025. Management also cited a materially improved debt maturity profile after refinancing initiatives in the prior twelve-month period. No capital-return actions were reported in the provided filing text.

The Company raised its full-year 2026 guidance. BHC now expects revenue of $10.790 - $11.040 billion and adjusted EBITDA of $4.050 - $4.175 billion. Bausch Health excluding Bausch + Lomb raised revenue, adjusted EBITDA, and adjusted cash flows from operations outlook, although tariff impacts remain an explicit uncertainty. Investors should monitor the durability of Salix growth, International organic performance, Solta's post-acquisition organic contribution, and the effect of tariff developments on the updated outlook.

Management, verbatim

The second quarter marks our thirteenth consecutive quarter of year-over-year growth in Revenue and Adjusted EBITDA for Bausch Health, excluding Bausch + Lomb, reflecting the strength of our portfolio, disciplined execution, and the dedication of our teams around the world. We delivered our highest Revenue and Adjusted EBITDA growth rates in the past three years, generated our strongest Adjusted Cash Flow from Operations since Q4 2024, and reduced Net Debt by one of our largest amounts since our 2022 debt refinancing. This performance strengthens our financial flexibility and supports continued investment in our business, our pipeline, and business development opportunities. We remain focused on driving long-term value creation.

Thomas J. Appio, Chief Executive Officer, Bausch Health

Not in the filing

stated, not guessed
  • Previous-release outlook was not provided, so comparison of actual results versus prior guidance is unavailable.
  • Gross profit and gross margin were not reported in the provided filing text.
  • Operating expenses were not reported in the provided filing text.
  • Tax rate was not reported in the provided filing text.
  • Total debt and net debt were not reported numerically in the provided filing text.
  • Free cash flow was not reported in the provided filing text.
  • Share repurchases and dividends were not reported in the provided filing text.
  • Prior-quarter comparisons were not reported for the presented key metrics.
  • A prior-year comparison for GAAP net income of $260 million was not reported in the provided filing text.
  • A prior-year comparison for Bausch Health excluding Bausch + Lomb adjusted cash flows from operations of $471 million was not reported in the provided filing text.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about BHC earnings dates

When is Bausch Health Companies's next earnings date?
AlphAI has no date for BHC yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.